| coordinators: | Gerard R. Dawson, United Kingdom |
| David Nutt, United Kingdom |
| |
Wednesday 2 September 2015
| 08:00 - 15:00
| D202 |
| 08:00 - 09:45 | Genetic influences in patient stratification and experimental medicine for brain disorder |
| | chair: | J.F. William Deakin, United Kingdom |
| |
| 08:00 - 08:30 | Implications of new genetics for experimental medicine and patient stratification |
| | speaker: | Anna Need, United Kingdom |
| |
| 08:30 - 09:00 | Impact of new genetics on drug design, development and trial |
| | speaker: | Alan Cross, United States |
| |
| 09:00 - 09:30 | What does cross species research tell us about brain disorders? |
| | speaker: | Jeffrey Glennon, Netherlands |
| |
| 10:15 - 12:00 | The experimental medicine agenda for industry 2016 and beyond |
| | chair: | Gerard R. Dawson, United Kingdom |
| |
| 10:15 - 10:45 | Challenges in quantifying neurosymptomatic approaches in the clinic |
| | speaker: | Darrel Pemberton, Belgium |
| |
| 10:45 - 11:15 | How can industry use fMRI to stratify patients and discover new treatments? |
| | speaker: | Andreas Meyer-Lindenberg, Germany |
| |
| 11:15 - 11:45 | Translation has to reverse before it can go forward |
| | speaker: | Hugh M. Marston, Germany |
| |
| 13:00 - 14:30 | Anticipated training needs for a new era of experimental medicine |
| | chair: | R. Hamish McAllister-Williams, United Kingdom |
| |
| 13:00 - 13:45 | Future skill needs for industry |
| | speaker: | Søgaard, Birgitte |
| |
| 13:45 - 14:30 | Future skill needs for academia |
| | speaker: | R. Hamish McAllister-Williams, United Kingdom |
| |
| 14:45 - 15:00 | General discussion and closing |